Sponsors (2)
This bill makes a large, targeted federal investment to expand prevention, treatment, workforce, and recovery supports for substance use disorders—especially in high‑overdose and Tribal areas—while creating significant new federal spending and distribution, implementation, and administrative challenges that could leave some communities underserved or strain state, insurer, and provider systems.
Millions of people with substance use disorders, plus state and local public‑health systems, will get a major, sustained increase in federal funding (including a $5.5B/year grant program plus multiple multi‑year appropriations) to expand prevention, treatment, recovery housing, surveillance, and related services.
Medicaid enrollees with opioid use disorder will face fewer administrative barriers to medications for addiction treatment (no prior authorization or other utilization controls), increasing faster access to MAT and reducing overdose risk.
People at risk of opioid overdose (Medicare, Medicaid, and commercial plan enrollees) will be able to obtain at least one FDA‑approved opioid reversal agent without deductible or coinsurance and without prior authorization, lowering out‑of‑pocket barriers in emergencies.
Taxpayers and the federal budget will bear very large, multi‑year new spending commitments (multiple programs totaling billions annually), raising deficit and budget‑prioritization concerns and creating pressure to offset costs elsewhere.
Many programs prioritize States or areas with the highest per‑capita drug‑poisoning deaths or use top‑10/state minimum formulas, which will leave other needy communities, rural areas, or localities with less funding and create geographic inequities.
State and local governments and smaller rural jurisdictions may lack the administrative, workforce, or delivery capacity to absorb and implement rapidly expanded grants and programs, limiting near‑term access to services despite new funding.
Based on analysis of 14 sections of legislative text.
Massively expands funding and program rules for SUD prevention and treatment, mandates insurer coverage of overdose reversal agents, raises Medicaid behavioral‑health rates, and launches a recovery‑housing CMMI demonstration.
Official title: Provide funding for programs and activities under the SUPPORT for Patients and Communities Act.
Introduced June 24, 2026 by Jeanne Shaheen · Last progress June 24, 2026
Creates a multi-part federal package to prevent and treat substance use disorders by funding treatment, recovery housing, prevention programs, data collection, law-enforcement mental-health supports, and demonstrations linking Medicaid managed care to recovery housing. It restricts certain payer barriers (no cost-sharing or prior authorization) for opioid overdose reversal agents and prohibits Medicaid matching for medication‑assisted treatment (MAT) if a State imposes utilization controls. Provides new and extended appropriations for many federal grant programs (FY2027–FY2032 in most cases), requires Medicaid to pay higher rates for certain behavioral health services for patients with substance use disorder between Oct 1, 2026 and Sep 30, 2030, and authorizes CMMI to test capitated budgets that pay for recovery housing in participating States to evaluate impacts on utilization, costs, and quality.